Tailored modulation of the inflammatory balance in COVID-19 patients admitted to the ICU?-a viewpoint
| Autor: | Peter E. Spronk, Marnix Kuindersma, Rocio Ramos Diaz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
ARDS Coronavirus disease 2019 (COVID-19) Critical Care Inflammatory response Inflammation Critical Care and Intensive Care Medicine Dexamethasone 03 medical and health sciences 0302 clinical medicine Viewpoint medicine Humans 030212 general & internal medicine Intensive care medicine Balance (ability) business.industry RC86-88.9 COVID-19 030208 emergency & critical care medicine Medical emergencies. Critical care. Intensive care. First aid medicine.disease Tailored treatment COVID-19 Drug Treatment Coronavirus Intensive Care Units Treatment Outcome Respiratory failure medicine.symptom business Respiratory Insufficiency medicine.drug |
| Zdroj: | Critical Care Critical Care, Vol 25, Iss 1, Pp 1-8 (2021) |
| ISSN: | 1466-609X |
| Popis: | A growing consensus seems to be emerging that dexamethasone is a crucial component in the treatment of COVID-19-associated oxygen-dependent respiratory failure. Although dexamethasone has an undeniably beneficial effect on the inflammatory response in a subgroup of patients, the potential negative effects of corticosteroids must also be considered. In view of these negative effects, we argue that a one-size-fits-all dexamethasone approach may be potentially harmful in specific subsets of patients with COVID-19-associated ARDS. We propose a different individually tailored treatment strategy based on the patient’s inflammatory response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink